In Vitro Lung Model Market By Type (2D Models, 3D Models), Application (Drug Screening, Toxicology), & Region for 2024-2031

In Vitro Lung Model Market Valuation - 2024-2031

The increased frequency of respiratory disorders and the need for effective therapeutic solutions are driving the growth of the in vitro lung model market. As illnesses like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer become increasingly common, there is an urgent need for novel drug research methodologies that can precisely model human lung physiology by enabling the market to surpass a revenue of USD 0.34 Billion valued in 2024 and reach a valuation of around USD 1.19 Billion by 2031.

Advances in tissue engineering and 3D bioprinting technology have considerably improved the capabilities of in vitro lung models, resulting in increased acceptance in a variety of industries including academic research, drug development, and toxicity testing. The creation of more advanced lung models that match the complex structure and function of human lungs enables more precise predictions of drug action and disease mechanisms by enabling the market to grow at a CAGR of 16.80% from 2024 to 2031.

In Vitro Lung Model Market: Definition/ Overview

An in vitro lung model is a laboratory tool that simulates the physiological and biochemical functions of human lung tissues. These models are critical for investigating respiratory disorders, drug combinations, and the effects of environmental pollutants without the ethical and practical constraints of in vivo research.

In vitro, lung models are transforming respiratory research and drug development by offering a regulated environment for studying lung physiology and disease processes. These models mirror the complex structure and function of human lung tissues allowing researchers to study how pollutants, infections, and medicinal chemicals affect lung cells.

The incorporation of organ-on-a-chip technology is intended to improve these models by allowing real-time monitoring of cellular responses and better simulating the human lung microenvironment. Furthermore, as personalized medicine gets pace, these models may be adjusted to reflect the genetic and phenotypic variability of patients, making them indispensable for creating targeted medicines.

Will the Rising Prevalence of Lung Diseases Drive the In Vitro Lung Model Market?

The increased frequency of lung disorders is a crucial driver for the in vitro lung model market owing to the growing burden of respiratory conditions worldwide. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) afflicted 384 million people worldwide in 2022 with the figure expected to increase by 40% by 2030. Furthermore, lung cancer incidence has climbed considerably, with the International Agency for Research on Cancer (IARC) reporting 2.2 million new cases in 2023, a 25% increase over the preceding decade. These numbers highlight the urgent need for improved disease models and medication development.

The pharmaceutical industry's shift towards more ethical and cost-effective drug development methods has also accelerated the adoption of in vitro lung models. According to the National Institutes of Health (NIH), the average cost of bringing a new drug to market exceeds $2 billion, with preclinical testing accounting for approximately 33% of this cost. In vitro lung models offer a solution by providing more accurate predictions of drug efficacy and toxicity before clinical trials. Additionally, research funding for developing advanced lung models has increased significantly, with the European Union's Horizon Europe program allocating €150 million specifically for organ-on-chip research, including lung models, for the period 2021-2027.

Will the Shortage of Trained Professionals Hamper the In Vitro Lung Model Market?

The shortage of skilled personnel is expected to have a substantial impact on the in vitro lung model industry. These models are critical for investigating respiratory disorders, medication responses, and toxicity because they provide more ethical and cost-effective alternatives to animal experimentation. A lack of properly qualified workers can result in inferior research findings, impeding the advancement of novel treatments and cures.

This lack may compound the difficulties of technology adoption and integration in R&D environments. Companies may struggle to integrate cutting-edge in vitro lung models if their personnel lacks proficiency in the relevant procedures and technologies. The use of outmoded models or protocols due to a lack of competent specialists may hinder the usefulness of research efforts and discourage investment in this field. As a result, the general innovation landscape could stagnate as firms may be hesitant to explore new approaches without confidence in their capacity to implement them effectively.

Category-Wise Acumens

Will the Efficiency and Comprehensive Nature Drive Growth in the Type Segment?

The 2D model type category dominated the market with a revenue share of more than 61.5%. This dominance can be traced to the inherent convenience and efficiency of two-dimensional cultures which are easier to develop and sustain than more complicated systems. Their accessibility has made them a popular choice among a wide range of researchers allowing for improvements in domains such as tissue engineering and the creation of complex culture systems. The simple construction of 2D models allows researchers to concentrate on study design and outcomes rather than technical problems allowing them to reach relevant conclusions faster.

2D cultures are especially useful for high-throughput screening which is an essential step in the drug discovery and testing process. This technology allows researchers to analyze a large number of substances or experimental situations in a short period, considerably boosting research and development. The ability to run multiple tests concurrently not only improves efficiency but also increases the likelihood of uncovering promising candidates for further examination.

Will the Flexibility and High Throughput Capabilities Drive the Application Segment?

The drug screening and toxicology category is expected to dominate the market owing to the versatility and high throughput capabilities provided by 2D cell models. These models are critical for quick screening of drug candidates allowing researchers to test many chemicals concurrently and efficiently. The ability to quickly examine a large number of samples improves the efficiency and effectiveness of drug discovery operations. Furthermore, 2D cell cultures allow for better manipulation and observation of cellular activities making them an appealing choice for first screenings.

While 2D models are extremely useful in the early phases of drug discovery, 3D cell models are gaining popularity due to their capacity to better simulate the in vivo environment. These sophisticated models offer a more physiologically appropriate setting for investigating cellular interactions, tissue architecture, and medication responses. This increased realism improves reproducibility and predictive accuracy in toxicology applications which are essential for understanding the potential side effects of new medications. 3D models have substantial advantages over traditional approaches because they bridge the gap between laboratory testing and real-world biological systems.

Gain Access into In Vitro Lung Model Market Report Methodology

Country/Region-wise Acumens

Will Increasing R&D Activities by Biotechnology and Pharmaceutical Companies Drive the Market in the North American Region?

North America dominates the in vitro lung model market primarily due to its robust research infrastructure and significant investments in pharmaceutical R&D. The region's leadership is particularly evident with the United States accounting for approximately 48% of global pharmaceutical R&D spending. The National Institutes of Health (NIH) further supports this growth with substantial funding for respiratory research, allocating USD 1.157 Billion in 2022 specifically for lung diseases research. Another significant driver is the rising focus on reducing animal testing, with the FDA Modernization Act 2.0 of 2022 allowing drug sponsors to use alternative testing methods

The rising prevalence of respiratory disorders has boosted research efforts; the CDC reports that chronic respiratory diseases impact nearly 40 million Americans demanding more efficient medication development methods. The COVID-19 pandemic has hastened this tendency, with the NIH investing more than USD 4.9 Billion in COVID-related research in 2021 including significant funding for lung-specific studies. Furthermore, the success rate of medication development utilizing in vitro models has shown promising results, with the FDA indicating that preclinical research employing human tissue models had a 25% higher predictive accuracy than traditional animal models.

Will Improvement in the Regulatory Framework Drive the Market in the Asia Pacific Region?

The Asia Pacific in vitro lung model market is growing at the highest rate globally owing mostly to stringent animal testing regulations and increased research funding. The region's rapid growth is most seen in nations like as China, Japan, and South Korea where legislative frameworks are expanding to enable alternative testing methods. For example, in 2019, China's National Medical Products Administration (NMPA) declared that it would accept non-animal testing data for cosmetic compounds resulting in a 90% reduction in animal testing standards.

The growing number of research publications and patents on the subject demonstrates the improvement of the regulatory landscape. The National Center for Biotechnology Information (NCBI) database shows that Asia Pacific researchers' publications on in vitro lung models increased by 65% between 2019 and 2023. South Korea's Ministry of Food and Drug Safety (MFDS) reported a 38% rise in authorized in vitro testing procedures between 2020 and 2023. Japan's investment in regenerative medicine and tissue engineering including lung models, will reach USD 23.8 Billion in 2022 according to the Ministry of Health, Labour, and Welfare.

Competitive Landscape

The In Vitro Lung Model Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the in vitro lung model market include:

Epithelix

MATTEK

Lonza

Emulate

AlveoliX AG

Nortis

CN Bio Innovations Ltd.

MIMETAS

InSphero

ATTC Global

Latest Developments

In November 2023, ImmuONE raised USD 2.48 Million to create a lung model as an alternative to animal drug testing. This is expected to expand the company's consumer base.

In December 2021, Lonza, a global pioneer in cell and gene therapy, and Agilent Technologies, a market leader in life sciences analytics, diagnostics, and applied chemicals, announced a collaboration. The cooperation aims to develop and integrate current and new analytical technologies into patient-scale cell therapy manufacturing workflows.

In Vitro Lung Model Market, By Category

• Type:
• 2D Models
• 3D Models
• Application:
• Drug Screening
• Toxicology

3D Model Development

• Others
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa